Symbiotec Pharmalab Limited is set to open its Initial Public Offering (IPO) for subscription on August 24, 2026. The company has fixed the price band at ₹938 to ₹988 per equity share, with each share having a face value of ₹2. The total offer size is approximately ₹1,757 crore.
The bidding period for anchor investors will open and close on August 21, 2026. For other investors, the IPO will open on August 24 and close on August 27, 2026. Investors can bid for a minimum of 15 equity shares, followed by bids in multiples of 15 shares.
Fresh Issue and Offer for Sale
The Symbiotec Pharmalab IPO comprises a fresh issue of equity shares worth up to ₹150 crore and an Offer for Sale (OFS) of shares worth up to ₹1,607 crore by existing shareholders.
Under the OFS, promoter selling shareholder Satwani Holdings LLP will sell shares worth up to ₹144 crore. Rosewood Investments will offer shares worth up to ₹988 crore, while India Business Excellence Fund III will sell shares worth up to ₹475 crore.
The company plans to use the net proceeds from the fresh issue towards the prepayment and/or repayment of certain outstanding borrowings, either fully or partially. The remaining funds will be used for general corporate purposes.
₹90 Discount for Eligible Employees
Eligible employees bidding under the Employee Reservation Portion will receive a ₹90 discount per equity share. The discount will apply to shares with a face value of ₹2 each.
The equity shares offered through the IPO are proposed to be listed on the BSE and NSE, with BSE designated as the stock exchange for the issue.
IPO Reservation for Investors
The IPO is being offered through the book-building process in accordance with applicable SEBI regulations. Not more than 50% of the Net Offer will be available for allocation to Qualified Institutional Buyers (QIBs).
The company, in consultation with the Book Running Lead Managers (BRLMs), may allocate up to 60% of the QIB Portion to Anchor Investors on a discretionary basis. Specific provisions have also been made for domestic mutual funds, life insurance companies and pension funds within the Anchor Investor Portion.
At least 15% of the Net Offer will be available for Non-Institutional Bidders, while at least 35% will be reserved for Retail Individual Bidders, subject to valid bids being received at or above the Offer Price.
ASBA Mandatory for Non-Anchor Investors
All investors other than Anchor Investors will be required to participate in the IPO through the Application Supported by Blocked Amount (ASBA) process. Investors applying through UPI will also need to provide their UPI ID, where applicable. The corresponding bid amount will be blocked in the investor’s bank account until the allotment process is completed.
Symbiotec Pharmalab filed its Red Herring Prospectus (RHP) on August 18, 2026 with the Registrar of Companies, Madhya Pradesh at Gwalior. Investors are advised to carefully review the RHP, including the risk factors and other offer-related details, before making an investment decision. Equity investments are subject to market risks.
Subscribe Deshwale on YouTube
